5FQL

Insights into Hunter syndrome from the structure of iduronate-2- sulfatase

Summary for 5FQL

• Entry DOI: 10.2210/pdb5fql/pdb
• Descriptor: IDURONATE-2-SULFATASE, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (7 entities in total)
• Functional Keywords: hydrolase, hunter syndrome
• Biological source: HOMO SAPIENS (HUMAN)
• Total number of polymer chains: 1
• Total formula weight: 62584.76

Authors

Demydchuk, M.,Hill, C.H.,Zhou, A.,Bunkoczi, G.,Stein, P.E.,Marchesan, D.,Deane, J.E.,Read, R.J. (deposition date: 2015-12-11, release date: 2017-01-18, Last modification date: 2025-04-09)

Primary citation

Demydchuk, M.,Hill, C.H.,Zhou, A.,Bunkoczi, G.,Stein, P.E.,Marchesan, D.,Deane, J.E.,Read, R.J.
Insights into Hunter syndrome from the structure of iduronate-2-sulfatase.
Nat Commun, 8:15786-15786, 2017

PubMed Abstract: Hunter syndrome is a rare but devastating childhood disease caused by mutations in the IDS gene encoding iduronate-2-sulfatase, a crucial enzyme in the lysosomal degradation pathway of dermatan sulfate and heparan sulfate. These complex glycosaminoglycans have important roles in cell adhesion, growth, proliferation and repair, and their degradation and recycling in the lysosome is essential for cellular maintenance. A variety of disease-causing mutations have been identified throughout the IDS gene. However, understanding the molecular basis of the disease has been impaired by the lack of structural data. Here, we present the crystal structure of human IDS with a covalently bound sulfate ion in the active site. This structure provides essential insight into multiple mechanisms by which pathogenic mutations interfere with enzyme function, and a compelling explanation for severe Hunter syndrome phenotypes. Understanding the structural consequences of disease-associated mutations will facilitate the identification of patients that may benefit from specific tailored therapies.

PubMed: 28593992
DOI: 10.1038/ncomms15786

Experimental method

X-RAY DIFFRACTION (2.3 Å)